On October 26, 2020 Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, reported a clinical collaboration agreement with Novartis to evaluate OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in combination with each of Kisqali (ribociclib) and Piqray (alpelisib) in patients with recurrent, locally advanced or metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer (Press release, Olema Pharmaceuticals, OCT 26, 2020, View Source [SID1234569078]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This collaboration with Novartis represents an important step toward our goal of advancing the clinical development of OP-1250," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "We look forward to exploring the potential of OP-1250 in combination with either Kisqali or Piqray in breast cancer patients."

Under the terms of the non-exclusive collaboration, Olema is responsible for conducting the trial. Novartis will supply its trial drugs and contribute to funding.